Replimune Group, Inc.

REPL ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2018 FY2017
Operating Activities
Net Income $-19.7M $-7.7M
Depreciation & Amortization $109.0K $122.0K
Depreciation — —
Amortization — —
Stock-Based Compensation $812.0K $208.0K
Net Cash from Operating Activities $-16.0M $-7.1M
Investing Activities
Capital Expenditures $136.0K $238.0K
Business Acquisitions — —
Net Cash from Investing Activities $-44.0M $-238.0K
Financing Activities
Dividends Paid — —
Stock Repurchases — —
Net Cash from Financing Activities $54.8M $15.0M
Net Change in Cash $-3.0M $6.3M
Free Cash Flow $-16.2M $-7.3M
← Newer Page 2 of 2 Older →